MOSCOW and HYDERABAD, India, Sept.
16, 2020 /PRNewswire/ -- The Russian Direct Investment Fund
(RDIF), Russia's sovereign wealth
fund, and Dr. Reddy's Laboratories Ltd. (Dr. Reddy's), a global
pharmaceutical company headquartered out of India, have agreed to cooperate on clinical
trials and distribution of Sputnik V vaccine in India. Upon regulatory approval in
India, RDIF shall supply to Dr.
Reddy's 100 million doses of the vaccine. The Sputnik V vaccine,
which is based on well-studied human adenoviral vector platform
with proven safety, is undergoing clinical trials for the
coronavirus pandemic. Deliveries could potentially begin in late
2020 subject to completion of successful trials and registration of
the vaccine by regulatory authorities in India.
The agreement between RDIF and Dr Reddy's reflects the growing
awareness of countries and organizations to have a diversified
anti-COVID vaccine portfolio to protect their populations.
Kirill Dmitriev, CEO of the
Russian Direct Investment Fund, said:
"We are very pleased to partner with Dr.Reddy's in India. Dr. Reddy's has had a very well
established and respected presence in Russia for over 25 years and is one of the
leading pharmaceutical companies in India. India
is amongst most severely impacted countries from COVID 19 and we
believe our human adenovirus dual vector platform will provide a
safe and scientifically validated option to India in the battle against COVID 19.
RDIF partners will receive an effective and safe drug to fight
the coronavirus. The platform of human adenoviral vectors, which is
the core of the Russian vaccine, has been tested in more than 250
clinical studies over decades, and it has been found safe with no
potential negative long-term consequences."
GV Prasad, Co-Chairman of Dr. Reddy's Laboratories
stated:
"We are pleased to partner with RDIF to bring the vaccine to
India. The Phase I and II results
have shown promise, and we will be conducting Phase-III trials in
India to meet the requirements of
the Indian regulators. Sputnik V vaccine could provide a credible
option in our fight against COVID 19 in India."
Prof. Sergey Tsarenko, Deputy
Chief Physician for Anesthesiology and Reanimation at Hospital No.
52 in Moscow, said:
"The main criteria for evaluating a vaccine are safety and
efficacy. In Sputnik V, safety is ensured by the use of human
adenoviral vectors, which we repeatedly encounter throughout our
lives. Efficacy is achieved by using two different human
adenoviruses sequentially, which differentiates this platform."
On August 11, the Sputnik V
vaccine developed by the Gamaleya National Research Institute of
Epidemiology and Microbiology was registered by the Ministry of
Health of Russia and became the
world's first registered vaccine against COVID-19 based on the
human adenoviral vectors platform. Detailed information on the
Sputnik V vaccine, the technological platform of human adenoviral
vectors, and other details are available at sputnikvaccine.com
On September 4, a research paper
on the results of Phase I and Phase II clinical trials of the
Sputnik V vaccine was published in The Lancet, one of the leading
international medical journals, demonstrating no serious adverse
effects and a stable immune response in 100% of participants.
Post-registration clinical trials of the Sputnik V vaccine
involving 40,000 volunteers are currently ongoing. More than 55,000
volunteers have applied to take part in post-registration trials.
The first results of these trials are expected to be published in
October - November 2020.
Russian Direct Investment Fund (RDIF) is
Russia's sovereign wealth fund
established in 2011 to make equity co-investments, primarily in
Russia, alongside reputable
international financial and strategic investors. RDIF acts as a
catalyst for direct investment in the Russian economy. RDIF's
management company is based in Moscow. Currently, RDIF has experience of the
successful joint implementation of more than 80 projects with
foreign partners totaling more than RUB1.9 tn and covering 95% of the regions of the
Russian Federation. RDIF portfolio
companies employ more than 800,000 people and generate revenues
which equate to more than 6% of Russia's GDP. RDIF has established joint
strategic partnerships with leading international co-investors from
more than 18 countries that total more than $40 bn. Further information can be found at
www.rdif.ru
About Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE:
500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines
for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary
Products – Dr. Reddy's offers a portfolio of products and services
including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Our major therapeutic
areas of focus are gastrointestinal, cardiovascular, diabetology,
oncology, pain management and dermatology. Dr. Reddy's operates in
markets across the globe. Our major markets include – USA, India,
Russia & CIS countries, and
Europe. For more information, log
on to: www.drreddys.com
Logo -
https://mma.prnewswire.com/media/1140939/Russian_Direct_Investment_Fund_Logo.jpg
Logo -
https://mma.prnewswire.com/media/1275375/Dr_Reddys_Logo.jpg